{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:33:31Z","timestamp":1791282811886,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270184"],"award-info":[{"award-number":["82270184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Drug resistance and relapse are still major challenges in acute myeloid leukemia (AML) because of the inability to effectively eradicate leukemia stem cells (LSCs). Senescence induction combined with immune killing may offer promising strategies for LSC eradication. However, whether and how drug-resistant LSCs retain stemness via senescence and immune regulation remains unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The immunoproteasome subunit <jats:italic>PSMB10<\/jats:italic> expression levels were analyzed by single-cell RNA-seq data, along with the bioinformatics analysis of publicly available AML datasets, and quantified using RT-qPCR and flow cytometry (FCM) analysis on clinical samples from AML patients. The cellular senescence was evaluated by the assays of cell proliferation, cell cycle, senescence-associated \u03b2-galactosidase activity, and senescence-associated secretory phenotype factors. In vitro T-cell killing assay was played to determine immune escape reprogramming of AML cells. FCM was conducted to estimate intracellular drug concentration and cellular apoptosis rates. Human AML xenografts and <jats:italic>PSMB10<\/jats:italic> knockout syngeneic mouse bone marrow transplantation models were utilized to investigate the function of PSMB10. Various techniques were employed for mechanism studies, including Lentivirus transduction or siRNA transfection, western blotting, co-immunoprecipitation assays, luciferase reporter assays, polysome profiling assays, quantitative proteomics, etc.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              <jats:italic>PSMB10<\/jats:italic> mRNA was significantly upregulated in the surviving nonsenescent LSCs, exhibiting a 13-fold increase compared to senescent LSCs following chemotherapy. The specific high expression of PSMB10 in post-chemotherapy nonsenescent LSCs predicts a poor AML prognosis. The genetic inactivation of <jats:italic>PSMB10<\/jats:italic> resulted in increased senescence and cytotoxic T lymphocyte (CTL) killing, as well as increased intracellular drug concentrations and drug-induced cellular senescence in different types of human AML cells, which also impeded human and murine leukemia initiation and stemness maintenance in vivo with a 19-fold decrease in the frequency of human LSCs and a 7.6-fold decrease of drug-resistant mouse LSCs, while normal hematopoietic cells remained unaffected. Mechanistically, the downregulation of PSMB10 boosted SLC22A16-mediated drug endocytosis and further induced chemotherapy drug-mediated senescence through the RPL6\/RPS6-MDM2-P21 pathway in AML cells. Additionally, downregulating PSMB10 also impeded MHC-I protein degradation-induced escape of CTL killing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>PSMB10 is a key candidate molecular target for eradicating drug-resistant LSCs via senescence and immune regulation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03420-9","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:19:47Z","timestamp":1748924387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["PSMB10 maintains the stemness of chemotherapeutic drug-resistant leukemia cells by inhibiting senescence and cytotoxic T lymphocyte-mediated killing in a ubiquitinated degradation manner"],"prefix":"10.1186","volume":"44","author":[{"given":"Xiao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyue","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"5","key":"3420_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/jco.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, L\u00f6wenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487\u201394. https:\/\/doi.org\/10.1200\/jco.2010.30.1820.","journal-title":"J Clin Oncol"},{"issue":"6330","key":"3420_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1126\/science.aam7304","volume":"355","author":"MA Dawson","year":"2017","unstructured":"Dawson MA. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science. 2017;355(6330):1147\u201352. https:\/\/doi.org\/10.1126\/science.aam7304.","journal-title":"Science"},{"issue":"3","key":"3420_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20(3):158\u201373. https:\/\/doi.org\/10.1038\/s41568-019-0230-9.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"3420_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129(12):1577\u201385. https:\/\/doi.org\/10.1182\/blood-2016-10-696054.","journal-title":"Blood"},{"issue":"5","key":"3420_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s12185-017-2221-5","volume":"105","author":"D Hanekamp","year":"2017","unstructured":"Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105(5):549\u201357. https:\/\/doi.org\/10.1007\/s12185-017-2221-5.","journal-title":"Int J Hematol"},{"issue":"2","key":"3420_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nm.3441","volume":"20","author":"J Ablain","year":"2014","unstructured":"Ablain J, Rice K, Soilihi H, De Reynies A, Minucci S, De Th\u00e9 H. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 2014;20(2):167\u201374. https:\/\/doi.org\/10.1038\/nm.3441.","journal-title":"Nat Med"},{"issue":"12","key":"3420_CR7","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1158\/2159-8290.Cd-21-0177","volume":"11","author":"HC Wu","year":"2021","unstructured":"Wu HC, R\u00e9rolle D, Berthier C, Hleihel R, Sakamoto T, Quentin S, et al. Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. Cancer Discov. 2021;11(12):3198\u2013213. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0177.","journal-title":"Cancer Discov"},{"issue":"2","key":"3420_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nm.3469","volume":"20","author":"V Bourdeau","year":"2014","unstructured":"Bourdeau V, Ferbeyre G. Engaging a senescent response to cure leukemia. Nat Med. 2014;20(2):123\u20134. https:\/\/doi.org\/10.1038\/nm.3469.","journal-title":"Nat Med"},{"issue":"2","key":"3420_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41375-023-02097-3","volume":"38","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wen J, Li Q, Peng D, Liao C, Ma X, et al. RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment. Leukemia. 2024;38(2):266\u201380. https:\/\/doi.org\/10.1038\/s41375-023-02097-3.","journal-title":"Leukemia"},{"issue":"5","key":"3420_CR10","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41375-018-0015-2","volume":"32","author":"D Peng","year":"2018","unstructured":"Peng D, Wang H, Li L, Ma X, Chen Y, Zhou H, et al. miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding. Leukemia. 2018;32(5):1180\u20138. https:\/\/doi.org\/10.1038\/s41375-018-0015-2.","journal-title":"Leukemia"},{"issue":"6","key":"3420_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2159-8290.Cd-20-1375","volume":"11","author":"C Duy","year":"2021","unstructured":"Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, et al. Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discov. 2021;11(6):1542\u201361. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1375.","journal-title":"Cancer Discov"},{"issue":"6","key":"3420_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P Van Galen","year":"2019","unstructured":"Van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176(6):1265-81.e24. https:\/\/doi.org\/10.1016\/j.cell.2019.01.031.","journal-title":"Cell"},{"issue":"3","key":"3420_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/35056572","volume":"2","author":"PM Kloetzel","year":"2001","unstructured":"Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol. 2001;2(3):179\u201387. https:\/\/doi.org\/10.1038\/35056572.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3420_CR14","doi-asserted-by":"publisher","first-page":"34019","DOI":"10.1038\/srep34019","volume":"6","author":"A Rouette","year":"2016","unstructured":"Rouette A, Trofimov A, Haberl D, Boucher G, Lavall\u00e9e VP, D\u2019angelo G, et al. Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers. Sci Rep. 2016;6:34019. https:\/\/doi.org\/10.1038\/srep34019.","journal-title":"Sci Rep"},{"issue":"1","key":"3420_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.stem.2020.04.001","volume":"27","author":"J Wang","year":"2020","unstructured":"Wang J, Li Y, Wang P, Han G, Zhang T, Chang J, et al. Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. Cell Stem Cell. 2020;27(1):81-97.e8. https:\/\/doi.org\/10.1016\/j.stem.2020.04.001.","journal-title":"Cell Stem Cell"},{"key":"3420_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1385\/1-59259-889-7:149","volume":"111","author":"A Krishan","year":"2005","unstructured":"Krishan A, Hamelik RM. Flow cytometric monitoring of fluorescent drug retention and efflux. Methods Mol Med. 2005;111:149\u201366. https:\/\/doi.org\/10.1385\/1-59259-889-7:149.","journal-title":"Methods Mol Med"},{"issue":"8","key":"3420_CR17","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood.V85.8.2147.bloodjournal8582147","volume":"85","author":"A Guerci","year":"1995","unstructured":"Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood. 1995;85(8):2147\u201353.","journal-title":"Blood."},{"issue":"14","key":"3420_CR18","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1158\/0008-5472.Can-03-3891","volume":"64","author":"A Van Zon","year":"2004","unstructured":"Van Zon A, Mossink MH, Schoester M, Scheper RJ, Sonneveld P, Wiemer EA. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein\/lung resistance-related protein (vault) expression. Cancer Res. 2004;64(14):4887\u201392. https:\/\/doi.org\/10.1158\/0008-5472.Can-03-3891.","journal-title":"Cancer Res"},{"issue":"1","key":"3420_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","volume":"38","author":"R Su","year":"2020","unstructured":"Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020;38(1):79-96.e11. https:\/\/doi.org\/10.1016\/j.ccell.2020.04.017.","journal-title":"Cancer Cell"},{"issue":"1","key":"3420_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/nar\/gkg034","volume":"31","author":"C Von Mering","year":"2003","unstructured":"Von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258\u201361. https:\/\/doi.org\/10.1093\/nar\/gkg034.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3420_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12943-019-1088-x","volume":"18","author":"R Jia","year":"2019","unstructured":"Jia R, Chai P, Wang S, Sun B, Xu Y, Yang Y, et al. m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 2019;18(1):161. https:\/\/doi.org\/10.1186\/s12943-019-1088-x.","journal-title":"Mol Cancer"},{"issue":"7728","key":"3420_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0615-z.","journal-title":"Nature"},{"issue":"7","key":"3420_CR23","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41418-018-0209-1","volume":"26","author":"NS Anstee","year":"2019","unstructured":"Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, Cory S. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Cell Death Differ. 2019;26(7):1316\u201331. https:\/\/doi.org\/10.1038\/s41418-018-0209-1.","journal-title":"Cell Death Differ"},{"issue":"6","key":"3420_CR24","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3892\/ijmm.2016.2552","volume":"37","author":"N Liu","year":"2016","unstructured":"Liu N, Wang C, Wang L, Gao L, Cheng H, Tang G, et al. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis. Int J Mol Med. 2016;37(6):1686\u201396. https:\/\/doi.org\/10.3892\/ijmm.2016.2552.","journal-title":"Int J Mol Med"},{"issue":"6","key":"3420_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.stem.2011.05.004","volume":"8","author":"LL Smith","year":"2011","unstructured":"Smith LL, Yeung J, Zeisig BB, Popov N, Huijbers I, Barnes J, et al. Functional crosstalk between Bmi1 and MLL\/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell. 2011;8(6):649\u201362. https:\/\/doi.org\/10.1016\/j.stem.2011.05.004.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"3420_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2007-09-113597","volume":"113","author":"J Faber","year":"2009","unstructured":"Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, Van Den Heuvel-Eibrink M, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009;113(11):2375\u201385. https:\/\/doi.org\/10.1182\/blood-2007-09-113597.","journal-title":"Blood"},{"issue":"2","key":"3420_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood-2011-03-341081","volume":"119","author":"Y Huang","year":"2012","unstructured":"Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C, et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood. 2012;119(2):388\u201398. https:\/\/doi.org\/10.1182\/blood-2011-03-341081.","journal-title":"Blood"},{"issue":"2","key":"3420_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/febs.16268","volume":"290","author":"S Aryal","year":"2023","unstructured":"Aryal S, Zhang Y, Wren S, Li C, Lu R. Molecular regulators of HOXA9 in acute myeloid leukemia. Febs j. 2023;290(2):321\u201339. https:\/\/doi.org\/10.1111\/febs.16268.","journal-title":"Febs j"},{"issue":"1","key":"3420_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12935-022-02767-9","volume":"22","author":"L Tang","year":"2022","unstructured":"Tang L, Peng L, Tan C, Liu H, Chen P, Wang H. Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential. Cancer Cell Int. 2022;22(1):349. https:\/\/doi.org\/10.1186\/s12935-022-02767-9.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"3420_CR30","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acs.jmedchem.8b01448","volume":"62","author":"S Depauw","year":"2019","unstructured":"Depauw S, Lambert M, Jambon S, Paul A, Peixoto P, Nhili R, et al. Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model. J Med Chem. 2019;62(3):1306\u201329. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01448.","journal-title":"J Med Chem"},{"issue":"7633","key":"3420_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, Mcleod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137. https:\/\/doi.org\/10.1038\/nature20598.","journal-title":"Nature"},{"issue":"20","key":"3420_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"issue":"6","key":"3420_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437\u201347. https:\/\/doi.org\/10.1038\/nrc1367.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3420_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1128\/mcb.18.2.753","volume":"18","author":"AS Lundberg","year":"1998","unstructured":"Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18(2):753\u201361. https:\/\/doi.org\/10.1128\/mcb.18.2.753.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"3420_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2015.08.008","volume":"17","author":"M Iwasaki","year":"2015","unstructured":"Iwasaki M, Liedtke M, Gentles AJ, Cleary ML. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell. 2015;17(4):412\u201321. https:\/\/doi.org\/10.1016\/j.stem.2015.08.008.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"3420_CR36","doi-asserted-by":"publisher","first-page":"a011536","DOI":"10.1101\/cshperspect.a011536","volume":"4","author":"DN Wilson","year":"2012","unstructured":"Wilson DN, Doudna Cate JH. The structure and function of the eukaryotic ribosome. Cold Spring Harb Perspect Biol. 2012;4(5):a011536. https:\/\/doi.org\/10.1101\/cshperspect.a011536.","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"23","key":"3420_CR37","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1093\/emboj\/cdg600","volume":"22","author":"Y Jin","year":"2003","unstructured":"Jin Y, Lee H, Zeng SX, Dai MS, Lu H. MDM2 promotes p21waf1\/cip1 proteasomal turnover independently of ubiquitylation. Embo j. 2003;22(23):6365\u201377. https:\/\/doi.org\/10.1093\/emboj\/cdg600.","journal-title":"Embo j"},{"issue":"24","key":"3420_CR38","doi-asserted-by":"publisher","first-page":"18407","DOI":"10.1074\/jbc.M109.059568","volume":"285","author":"H Xu","year":"2010","unstructured":"Xu H, Zhang Z, Li M, Zhang R. MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem. 2010;285(24):18407\u201314. https:\/\/doi.org\/10.1074\/jbc.M109.059568.","journal-title":"J Biol Chem"},{"issue":"3","key":"3420_CR39","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/nar\/gkt971","volume":"42","author":"D Bai","year":"2014","unstructured":"Bai D, Zhang J, Xiao W, Zheng X. Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress. Nucleic Acids Res. 2014;42(3):1799\u2013811. https:\/\/doi.org\/10.1093\/nar\/gkt971.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3420_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2217\/14622416.8.6.567","volume":"8","author":"S Lal","year":"2007","unstructured":"Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007;8(6):567\u201375. https:\/\/doi.org\/10.2217\/14622416.8.6.567.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"3420_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/10428194.2020.1839650","volume":"62","author":"JE Meg\u00edas-Vericat","year":"2021","unstructured":"Meg\u00edas-Vericat JE, Mart\u00ednez-Cuadr\u00f3n D, Herrero MJ, Rodr\u00edguez-Veiga R, Solana-Altabella A, Boluda B, et al. Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2021;62(3):659\u201368. https:\/\/doi.org\/10.1080\/10428194.2020.1839650.","journal-title":"Leuk Lymphoma"},{"key":"3420_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbi.2021.05.015","volume":"97","author":"HR Meng","year":"2021","unstructured":"Meng HR, Suenaga T, Edamura M, Fukuda A, Ishida Y, Nakahara D, Murakami G. Functional MHCI deficiency induces ADHD-like symptoms with increased dopamine D1 receptor expression. Brain Behav Immun. 2021;97:22\u201331. https:\/\/doi.org\/10.1016\/j.bbi.2021.05.015.","journal-title":"Brain Behav Immun"},{"issue":"6268","key":"3420_CR43","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/344742a0","volume":"344","author":"M Zijlstra","year":"1990","unstructured":"Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature. 1990;344(6268):742\u20136. https:\/\/doi.org\/10.1038\/344742a0.","journal-title":"Nature"},{"key":"3420_CR44","doi-asserted-by":"publisher","first-page":"100703","DOI":"10.1016\/j.drup.2020.100703","volume":"52","author":"L Long","year":"2020","unstructured":"Long L, Assaraf YG, Lei ZN, Peng H, Yang L, Chen ZS, Ren S. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resist Updat. 2020;52:100703. https:\/\/doi.org\/10.1016\/j.drup.2020.100703.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"3420_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","volume":"31","author":"J Prada-Arismendy","year":"2017","unstructured":"Prada-Arismendy J, Arroyave JC, R\u00f6thlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31(1):63\u201376. https:\/\/doi.org\/10.1016\/j.blre.2016.08.005.","journal-title":"Blood Rev"},{"issue":"12","key":"3420_CR46","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","volume":"116","author":"S Abbas","year":"2010","unstructured":"Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122\u20136. https:\/\/doi.org\/10.1182\/blood-2009-11-250878.","journal-title":"Blood"},{"key":"3420_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1477-5956-11-39","volume":"11","author":"J Bai","year":"2013","unstructured":"Bai J, He A, Zhang W, Huang C, Yang J, Yang Y, et al. Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling. Proteome Sci. 2013;11:39. https:\/\/doi.org\/10.1186\/1477-5956-11-39.","journal-title":"Proteome Sci"},{"issue":"2","key":"3420_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1600-0609.2011.01716.x","volume":"88","author":"J Markov\u00e1","year":"2012","unstructured":"Markov\u00e1 J, Michkov\u00e1 P, Bur\u010dkov\u00e1 K, B\u0159ezinov\u00e1 J, Michalov\u00e1 K, Dohnalov\u00e1 A, et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol. 2012;88(2):128\u201335. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01716.x.","journal-title":"Eur J Haematol"},{"issue":"1","key":"3420_CR49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.leu.2402708","volume":"17","author":"L Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz L, Nomded\u00e9u JF, Villamor N, Guardia R, Colomer D, Ribera JM, et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia. 2003;17(1):76\u201382. https:\/\/doi.org\/10.1038\/sj.leu.2402708.","journal-title":"Leukemia"},{"key":"3420_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","volume":"160","author":"J Zhao","year":"2016","unstructured":"Zhao J. Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther. 2016;160:145\u201358. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.02.008.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3420_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.stem.2018.12.009","volume":"24","author":"BC Prager","year":"2019","unstructured":"Prager BC, Xie Q, Bao S, Rich JN. Cancer Stem Cells: The Architects of the Tumor Ecosystem. Cell Stem Cell. 2019;24(1):41\u201353. https:\/\/doi.org\/10.1016\/j.stem.2018.12.009.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"3420_CR52","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","volume":"18","author":"NK Lytle","year":"2018","unstructured":"Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18(11):669\u201380. https:\/\/doi.org\/10.1038\/s41568-018-0056-x.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3420_CR53","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","volume":"35","author":"R Nair","year":"2021","unstructured":"Nair R, Salinas-Illarena A, Baldauf HM. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia. 2021;35(2):299\u2013311. https:\/\/doi.org\/10.1038\/s41375-020-01069-1.","journal-title":"Leukemia"},{"issue":"1","key":"3420_CR54","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-023-01907-7","volume":"22","author":"N Tub\u00edo-Santamar\u00eda","year":"2023","unstructured":"Tub\u00edo-Santamar\u00eda N, Jayavelu AK, Schnoeder TM, Eifert T, Hsu CJ, Perner F, et al. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Mol Cancer. 2023;22(1):196. https:\/\/doi.org\/10.1186\/s12943-023-01907-7.","journal-title":"Mol Cancer"},{"issue":"1","key":"3420_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/j.1460-2075.1984.tb01767.x","volume":"3","author":"J Kruppa","year":"1984","unstructured":"Kruppa J, Clemens MJ. Differential kinetics of changes in the state of phosphorylation of ribosomal protein S6 and in the rate of protein synthesis in MPC 11 cells during tonicity shifts. Embo j. 1984;3(1):95\u2013100. https:\/\/doi.org\/10.1002\/j.1460-2075.1984.tb01767.x.","journal-title":"Embo j"},{"issue":"9","key":"3420_CR56","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","volume":"89","author":"CP Leith","year":"1997","unstructured":"Leith CP, Kopecky KJ, Godwin J, Mcconnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy A Southwest Oncology Group study. Blood. 1997;89(9):3323\u20139.","journal-title":"Blood"},{"issue":"2","key":"3420_CR57","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0021-9258(19)75806-2","volume":"262","author":"K Ueda","year":"1987","unstructured":"Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM. Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987;262(2):505\u20138.","journal-title":"J Biol Chem."},{"issue":"1","key":"3420_CR58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13578-022-00941-0","volume":"12","author":"J Kallenbach","year":"2022","unstructured":"Kallenbach J, Atri Roozbahani G, Heidari Horestani M, Baniahmad A. Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. Cell Biosci. 2022;12(1):200. https:\/\/doi.org\/10.1186\/s13578-022-00941-0.","journal-title":"Cell Biosci"},{"key":"3420_CR59","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-biochem-060410-150257","volume":"82","author":"RJ Tomko","year":"2013","unstructured":"Tomko RJ, Jr., Hochstrasser M. Molecular architecture and assembly of the eukaryotic proteasome. Annu Rev Biochem. 2013;82:415\u201345. https:\/\/doi.org\/10.1146\/annurev-biochem-060410-150257.","journal-title":"Annu Rev Biochem"},{"issue":"21","key":"3420_CR60","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1038\/onc.2013.224","volume":"33","author":"XW Yang","year":"2014","unstructured":"Yang XW, Wang P, Liu JQ, Zhang H, Xi WD, Jia XH, Wang KK. Coordinated regulation of the immunoproteasome subunits by PML\/RAR\u03b1 and PU.1 in acute promyelocytic leukemia. Oncogene. 2014;33(21):2700\u20138. https:\/\/doi.org\/10.1038\/onc.2013.224.","journal-title":"Oncogene."},{"issue":"12","key":"3420_CR61","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1002\/eji.201546100","volume":"45","author":"S Joyce","year":"2015","unstructured":"Joyce S. Immunoproteasomes edit tumors, which then escapes immune recognition. Eur J Immunol. 2015;45(12):3241\u20135. https:\/\/doi.org\/10.1002\/eji.201546100.","journal-title":"Eur J Immunol"},{"issue":"631","key":"3420_CR62","doi-asserted-by":"publisher","first-page":"eabg8070","DOI":"10.1126\/scitranslmed.abg8070","volume":"14","author":"MC Lahman","year":"2022","unstructured":"Lahman MC, Schmitt TM, Paulson KG, Vigneron N, Buenrostro D, Wagener FD, et al. Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency. Sci Transl Med. 2022;14(631):eabg8070. https:\/\/doi.org\/10.1126\/scitranslmed.abg8070.","journal-title":"Sci Transl Med."},{"issue":"1","key":"3420_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1440-1746.2003.02921.x","volume":"18","author":"T Miyagi","year":"2003","unstructured":"Miyagi T, Tatsumi T, Takehara T, Kanto T, Kuzushita N, Sugimoto Y, et al. Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. J Gastroenterol Hepatol. 2003;18(1):32\u201340. https:\/\/doi.org\/10.1046\/j.1440-1746.2003.02921.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"3420_CR64","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21873","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian HM, Dinardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2024. https:\/\/doi.org\/10.3322\/caac.21873.","journal-title":"CA Cancer J Clin"},{"key":"3420_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fmicb.2015.00021","volume":"6","author":"MK Mccarthy","year":"2015","unstructured":"Mccarthy MK, Weinberg JB. The immunoproteasome and viral infection: a complex regulator of inflammation. Front Microbiol. 2015;6:21. https:\/\/doi.org\/10.3389\/fmicb.2015.00021.","journal-title":"Front Microbiol"},{"issue":"3","key":"3420_CR66","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11(3):239\u201353. https:\/\/doi.org\/10.2174\/156800911794519752.","journal-title":"Curr Cancer Drug Targets"},{"issue":"13","key":"3420_CR67","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.Can-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383\u201391. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-4086.","journal-title":"Cancer Res"},{"issue":"21","key":"3420_CR68","doi-asserted-by":"publisher","first-page":"11595","DOI":"10.3390\/ijms222111595","volume":"22","author":"J Wang","year":"2021","unstructured":"Wang J, Fang Y, Fan RA, Kirk CJ. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism. Int J Mol Sci. 2021;22(21):11595. https:\/\/doi.org\/10.3390\/ijms222111595.","journal-title":"Int J Mol Sci."},{"issue":"9","key":"3420_CR69","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.Ccr-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734\u201343. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-1950.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3420_CR70","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1021\/acs.jmedchem.8b01884","volume":"62","author":"BT Xin","year":"2019","unstructured":"Xin BT, Huber EM, De Bruin G, Heinemeyer W, Maurits E, Espinal C, et al. Structure-Based Design of Inhibitors Selective for Human Proteasome \u03b22c or \u03b22i Subunits. J Med Chem. 2019;62(3):1626\u201342. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01884.","journal-title":"J Med Chem"},{"issue":"1","key":"3420_CR71","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12964-023-01282-2","volume":"21","author":"M Bakhtiyari","year":"2023","unstructured":"Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M, et al. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Commun Signal. 2023;21(1):252. https:\/\/doi.org\/10.1186\/s12964-023-01282-2.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"3420_CR72","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","volume":"32","author":"D Forte","year":"2020","unstructured":"Forte D, Garc\u00eda-Fern\u00e1ndez M, S\u00e1nchez-Aguilera A, Stavropoulou V, Fielding C, Mart\u00edn-P\u00e9rez D, et al. Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metab. 2020;32(5):829-43.e9. https:\/\/doi.org\/10.1016\/j.cmet.2020.09.001.","journal-title":"Cell Metab"},{"issue":"1","key":"3420_CR73","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-018-0738-y","volume":"37","author":"W Lu","year":"2018","unstructured":"Lu W, Wan Y, Li Z, Zhu B, Yin C, Liu H, et al. Growth differentiation factor 15 contributes to marrow adipocyte remodeling in response to the growth of leukemic cells. J Exp Clin Cancer Res. 2018;37(1):66. https:\/\/doi.org\/10.1186\/s13046-018-0738-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3420_CR74","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12964-023-01231-z","volume":"21","author":"R Sabbah","year":"2023","unstructured":"Sabbah R, Saadi S, Shahar-Gabay T, Gerassy S, Yehudai-Resheff S, Zuckerman T. Abnormal adipogenic signaling in the bone marrow mesenchymal stem cells contributes to supportive microenvironment for leukemia development. Cell Commun Signal. 2023;21(1):277. https:\/\/doi.org\/10.1186\/s12964-023-01231-z.","journal-title":"Cell Commun Signal"},{"issue":"D1","key":"3420_CR75","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y, et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2022;50(D1):D1522\u20137. https:\/\/doi.org\/10.1093\/nar\/gkab1081.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3420_CR76","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47(D1):D1211\u20137. https:\/\/doi.org\/10.1093\/nar\/gky869.","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03420-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:19:48Z","timestamp":1748924388000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03420-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3420"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03420-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Primary AML patient samples and healthy donor controls were obtained with informed consent from Wuhan Union Hospital, and the study was approved by the Ethics Committee of Union Hospital, Huazhong University of Science and Technology (Number # 0574).All mice were housed under pathogen-free conditions in accordance with the guidelines of the Animal Care and Ethics Committee at Huazhong University of Science and Technology. All experiments were conducted following approval from the Ethics Committee of Huazhong University of Science and Technology (Number # 4131).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}